Lite Strategy, Inc. filings document the company’s public-company transition, operating results, Litecoin treasury strategy, and capital-allocation actions. Form 8-K disclosures include furnished financial results, the board-authorized common stock repurchase program, and equity securities activity tied to pre-funded warrants issued in a private placement.
The filings also cover governance and compensation matters, including annual meeting voting results, director elections and resignation, executive appointment to chief executive officer and the board, stock option grants, and approval of the 2026 Omnibus Equity Compensation Plan. SEC reports identify MEI Pharma, Inc. as the company’s former name and support the current Lite Strategy identity.
Lite Strategy, Inc. reported that an investor exercised a portion of previously issued pre-funded warrants. These warrants were originally issued on July 22, 2025 in a private PIPE offering at an offering price of $3.4199 per pre-funded warrant for up to 6,022,869 shares of common stock.
On September 10, 2025, the investor exercised 1,595,000 pre-funded warrants in a cashless transaction, receiving 1,594,944 shares of Lite Strategy common stock. The warrants and the shares issued upon exercise were issued in transactions relying on private offering exemptions under Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D.